|
Alpha-1-antitrypsin
as a novel target for immunodeficiency
Alpha-1-antitrypsin as a novel target for human
immunodeficiency virus type 1 - target evaluation
and drug discovery strategies.
The endogenous serine protease inhibitor,
alpha-1-antitrypsin, represents a novel target for
the treatment of HIV-infection. Physiological
concentrations of alpha-1-antitrypsin inhibit HIV-1
production in chronically infected monocytes, block
cellular infection, and reduce virus replication in
freshly infected peripheral blood mononuclear cells.
Furthermore HIV-1 replication is considerably
enhanced in blood from individuals with hereditary
alpha-1-antitrypsin deficiency. A dossier has now
been described which:
> Analyzes the excellent proof of concept for
targeting serine protease as HIV therapies
> Establishes the pharmaceutical novelty of
serine proteases as targets for HIV infection
> Suggests screening architectures to develop
therapeutic candidates
> Identifies academic labs that could help
expedite screening or provide biological material
(such as human material) to fully characterize the
clinical potential of hits
Price: $100.00 Order
here!
|
$100.00 online format
Order
here!
|
Projects
such as these are overviewed in full DiscoveryDossiers.
Interested
in the production and circulation of a DiscoveryDossier on
your research, technology or products?
DiscoveryDossiers
~ TherapeuticsAdvances ~ PharmaceuticalSolutions
~ LeadDiscovery ~
Purchase
DiscoveryDossiers
LeadDiscovery
and BioPortfolio aims to provide reliable, insightful
analysis on the biotechnology industry. However, this
information is provided "as is" and no
representations or warranties either express or implied of
completeness, accuracy, or of any other nature are made
with respect to this information. This information is
neither an offer to sell nor a solicitation to buy the
securities of any company. This information contains
forward-looking statements, which involve risks and
uncertainties which may not be listed. The biotechnology
industry is an emerging industry and the securities of the
companies mentioned in this report have a very high degree
of risk and volatility. For this reason, this information
is supplied on the condition that the reader will make his
or her own determination as to its suitability for any
purpose prior to any use of this information. The
employees and officers of LeadDiscovery and BioPortfolio
may hold positions in some or all of the stocks discussed
in this report.
This
abstract has been produced by LeadDiscovery Ltd. Founded
by life scientists for life scientists we aim to help
industry identify cutting edge drug discovery options and
academic/biotech institutions maximize the potential of
their research. Abstracts strictly reflect the opinion of
LeadDiscovery's editorial panel. While all reasonable
efforts are made to ensure the accuracy of information
provided LeadDiscovery and the publisher BioPortfolio,
takes no responsibility for incorrect or misleading
information. LeadDiscovery is designed for educational and
drug development purposes only and is not intended or
designed to offer medical advice or advice of any sort,
and must not be used for such purpose. The information
provided through LeadDiscovery and BioPortfolio should not
be used for diagnosing or treating a health problem or a
disease and no reliance should be placed on any
information contained in this abstract or elsewhere on
LeadDiscovery's and BioPortfolio's website. It is not
intended to be a substitute for professional care. If you
have or suspect you may have a health problem, you should
consult your physician or other health care provider.
|
|
| |
Nothing in this website should be used in place of personal medical
advice from your own qualified medical practitioner. See
User
Agreement
Send comments and feedback to:
Peter Barfoot
Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472 |
All rights reserved. All other trademarks recognized.
BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK.
No.3312883 VAT No. GB 744 6483 10
Copyright © 1997-2008 - BioPortfolio Limited.
|
|
|
